Cortes D, Chirivi M, Wang S, Contreras G A
Department of Large Animal Clinical Sciences, Michigan State University, East Lansing 48824.
Center for Statistical Training and Consulting, Michigan State University, East Lansing 48824.
JDS Commun. 2023 Feb 9;4(2):116-120. doi: 10.3168/jdsc.2022-0285. eCollection 2023 Mar.
The objective of this randomized clinical study was to evaluate the effects of periparturient administration of pegbovigrastim (recombinant bovine granulocyte colony stimulating factor; PEG) on postpartum health and reproductive outcomes in dairy cows carrying transferred embryos. A total of 60 multiparous Jersey cows (second parity n = 21, >second parity n = 39) that were in vitro-fertilized embryo recipients were enrolled. Animals were selected from a commercial herd and assigned to 1 of 2 treatments: (1) PEG (n = 31), which received a subcutaneous injection of 15 mg of PEG 7 d before expected calving and a second dose within 1 h of parturition; or (2) CON, untreated control (n = 29). Parturition was induced pharmacologically in all cows at 280 d of pregnancy with 500 μg of cloprostenol and 25 mg of dexamethasone intramuscularly. Cow health was monitored daily during the periparturient period and included assessment for retained fetal membranes within 24 h after calving and metritis until 20 d in milk. Descriptive statistics were calculated, to determine the incidence of postpartum diseases, causes of culling, and early-lactation reproductive outcomes, including number of inseminations, days to first heat, days to first service, and interval from calving to conception. The Wilcoxon rank sum test was used to assess treatment effects on early-lactation reproductive performance outcomes. The overall incidence of metritis in this cohort of cows was 17.14%. Animals treated with PEG tended to have more cases of metritis (25%) compared with CON (8.8%). Mastitis incidence in PEG was 19.35% compared with CON at 27.59%. These data suggest that in this dairy, with embryo-recipient cows induced to calve at 280 d of pregnancy, the administration of 2 doses of PEG tended to increase postpartum metritis but had no effect on mastitis incidence, culling rate, or early-lactation reproductive outcomes.
这项随机临床研究的目的是评估围产期给予培戈维司亭（重组牛粒细胞集落刺激因子；PEG）对移植胚胎的奶牛产后健康和繁殖性能的影响。总共纳入了60头经体外受精的胚胎受体经产泽西奶牛（第二胎n = 21，二胎以上n = 39）。这些动物选自一个商业牛群，并被分配到两种处理中的一种：（1）PEG组（n = 31），在预计产犊前7天皮下注射15 mg PEG，并在分娩后1小时内注射第二剂；或（2）CON组，未处理的对照组（n = 29）。所有奶牛在妊娠280天时用500 μg氯前列醇和25 mg地塞米松肌肉注射进行药物引产。在围产期每天监测奶牛健康状况，包括产后24小时内评估胎膜残留情况以及直至产奶20天时评估子宫内膜炎情况。计算描述性统计数据，以确定产后疾病的发生率、淘汰原因以及早期泌乳繁殖性能，包括输精次数、首次发情天数、首次配种天数以及从产犊到受孕的间隔时间。采用Wilcoxon秩和检验来评估处理对早期泌乳繁殖性能结果的影响。该组奶牛子宫内膜炎的总体发生率为17.14%。与CON组（8.8%）相比，接受PEG治疗的动物子宫内膜炎病例往往更多（25%）。PEG组乳腺炎发生率为19.35%，而CON组为27.59%。这些数据表明，在这个奶牛场中，对于妊娠280天时诱导产犊的胚胎受体奶牛，给予两剂PEG往往会增加产后子宫内膜炎，但对乳腺炎发生率、淘汰率或早期泌乳繁殖性能没有影响。
